secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2021-08-18T23:59:59+00:00
Accession:  0001104659-21-107375
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax appoints Jim Kelly as CFO and Nasir Egal as SVP of Quality Assurance
----------------------------------------------------------------------------

- Jim Kelly appointed EVP, CFO and Treasurer effective August 16, 2021; John Trizzino returns to CCO/CBO role.
- Kelly previously CFO at Supernus Pharmaceuticals and Vanda Pharmaceuticals; 25+ years industry experience.
- Kelly receives $490k base salary, 45% target bonus, $100k signing bonus (pro-rated if leaves within 24 months), plus stock awards and severance terms.
- Nasir Egal appointed SVP of Quality Assurance; former Head of Global Quality External Affairs at Sanofi and FDA research scientist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465921107375/0001104659-21-107375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465921107375/tm2125353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-107375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer